Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: sjemmeri who wrote (4590)	2/17/2006 12:08:03 PM
From: keokalani'nui	Respond to of 4974

Don't know if corus really had the goods, but hate to see any potential treatment for CF go unfunded.

To: sjemmeri who wrote (4590)	4/13/2006 1:49:27 AM
From: dr.praveen	Respond to of 4974

Gilead Invests $25 Million in Corus Pharma Wednesday April 12, 4:00 pm ET Establishes Equity Position in Company With Late-Stage Product Candidate for Cystic Fibrosis biz.yahoo.com FOSTER CITY, Calif. & SEATTLE--(BUSINESS WIRE)--April 12, 2006--Gilead Sciences, Inc. (Nasdaq:GILD - News) and Corus Pharma, Inc. today announced that Gilead has invested $25 million in Corus, a privately-held Seattle-based company focused on the development of novel drugs for respiratory diseases. In return for the investment, Gilead will receive preferred shares in Corus and will become the second largest shareholder in the company. Gilead will also have an exclusive option to purchase the remaining shares of Corus at a pre-specified price. Corus' lead product candidate, Cayston(TM) (aztreonam lysine for inhalation), is an inhaled antibiotic with activity against gram-negative bacteria including Pseudomonas aeruginosa, which can cause lung infections in patients with cystic fibrosis (CF). Corus is currently enrolling Phase III studies to evaluate the product as a potential treatment for CF-related pulmonary infections. Aztreonam lysine for inhalation was granted orphan drug status by the U.S. Food & Drug Administration in March 2002.